JOHNSON & JOHNSON $JNJ Q3’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $25.4B (Est. $25.28B) 🟢; +5.9% YoY 🔹 Adj. EPS: $2.59 (Est. $2.54) 🟢; -7.5% YoY 🔹 GAAP EPS: $0.09; -95.8% YoY Raises FY26 Guide: 🔹 Revenue: $101.0B-$101.4B (Est. $101.29B) 🟡 🔹 Adj. EPS: $11.05-$11.15 (Est. $11.08) 🟡 🔹 Adj. Oper Sales Growth: +6.4%-+6.8% Cash Flow: 🔹 Free Cash Flow YTD: ~$15.1B Segment Sales: 🔹 Innovative Medicine: $16.76B (Est. $16.59B) 🟢 🔹 MedTech: $8.64B (Est. $8.77B) 🔴; +2.5% YoY Regional Sales: 🔹 U.S.: $14.96B; +9.1% YoY 🔹 International: $10.44B; +1.5% YoY Key Products: 🔹 DARZALEX WW: $4.24B (Est. $4.33B) 🔴 🔹 TREMFYA WW: $2.4B (Est. $2.24B) 🟢; +68.3% YoY 🔹 CARVYKTI WW: $710M (Est. $708.49M) 🟢 Other Q3 Metrics: 🔹 Operational Sales Growth: +6.0% 🔹 Adj. Oper Sales Growth: +6.1% 🔹 Adj. Net Earnings: $6.34B (Est. $6.23B) 🟢 Key Updates: 🔹 One-time special charge reflects the proposed talc litigation resolution, Firefly Bio acquisition and Sail Biomedicines collaboration; adjusted EPS also reflects these M&A deals. 🔹 OTTAVA received market authorization as the world’s first table-integrated soft tissue robotic system; IMAAVY was approved in wAIHA and RYBREVANT FASPRO received priority review. Comments: 🔸 “In the third quarter, we advanced breakthroughs that will redefine care for patients, from delivering one of our most transformative MedTech innovations with OTTAVA to reporting positive Phase 3 results in multiple myeloma.”